Efficacy and safety of treatment with new ARB Azilsartan in hypertension patients who did not show target blood pressure by other ARBs.

Efficacy and safety of treatment with new ARB Azilsartan in hypertension patients who did not show target blood pressure by other ARBs. - Study of Switching to Azilsartan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008700

Enrollment

Registered

2012-08-20

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensives

Interventions

Switching to Azilsartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 1) 20 years-old over, the patients who have 140/90 mmHg or more. In the case of diabetes, 130/80 or more. (JSH2009) 2) Hypertensives in ARB usual dose treatment

Exclusion criteria

Exclusion criteria: 1)Past medical history of hypersensitivity to azilsartan 2)Pregnant, lactating, and possibly pregnant women and those planning to become pregnant 3)Judged as ineligible by clinical investigators

Design outcomes

Primary

Measure	Time frame
blood pressure at 0, 2, 4 and 8 weeks after starting of treatment	—

Secondary

Measure	Time frame
Urinary protein or albumin, Serum creatinine and eGFR, electrolytes Na/K/Cl, Cystatin C, BNP, Safety at 0, 2, 4 and 8 weeks after starting of treatment	—

Countries

Japan

Contacts

Public ContactYusuke Suzuki

Juntendo University Faculty of Medicine Department of Internal Medicine, Division of Nephrology

Chiken@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026